Physician profile
Amna Khan
NPI 1356531024
$39,285.23
in general payments reported to CMS, 2019-2025
8 companies · $9,429 in 2025
The $9,429 reported for 2025 was more than what 90% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.48 · 2021: $57.30 · 2022: $18K · 2023: $2,441 · 2024: $9,741 · 2025: $9,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $13K · Honoraria: $7,450 · Food and Beverage: $932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $13,229.32 |
| Honoraria | $7,450.00 |
| Food and Beverage | $931.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $39,033.94 | 2022-2025 | Monoferric |
| Kyowa Kirin, INC. | $111.17 | 2023 | |
| Lilly USA, LLC | $37.59 | 2020-2023 | Mounjaro |
| Eisai INC. | $35.48 | 2021 | |
| Electromed, INC. | $28.47 | 2025 | Smartvest |
| Vapotherm INC | $21.82 | 2021 | |
| Genentech USA, INC. | $16.76 | 2024 | Actemra |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amna Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.